


BUS-TBNA PREVENTS MEDIASTINOSCOPIES IN THE DIAGNOSIS OF ISOLATED MEDIASTINAL LYMPHADENOPATHY: A PROSPECTIVE TRIAL

Neal Navani, David R. Lawrence, Shyam Kolvekar, Martin Hayward, Dorcas McAsey, Gabrijela Kocjan, Mary Falzon, Arrigo Capitanio,
Penny Shaw, Stephen Morris, Rumana Z. Omar, Sam M. Janes, on behalf of the REMEDY trial investigators

ONLINE DATA SUPPLEMENT

Supplementary Figure E1: Decision tree model of patients with isolated mediastinal lymphadenopathy. We assume a sensitivity of 100% for the mediastinoscopy strategy. Probabilities for the EBUS-TBNA strategy are obtained from the REMEDY trial.



Supplementary Table E1: Cost of the EBUS-TBNA procedure to the NHS, assuming 250 cases per year and 3 cases per session. All costs are measured in 2010-11 £UK.

1 £UK = 1.58 USD (1st February 2012)

Resource	Cost per year (£)	Cost per procedure (£)	Notes
Capital costs of 2 EBUS echoendoscopes	28,000	112	Total cost of £140,000 (including 1 processor) assumed to be spread over 5 years
EBUS-TBNA needle	43,750	175	Source: manufacturer's price
Maintenance contract	9000	36	Source: UCLH
2 Consultants for 2.5 sessions per week	50,000	200	Source: UCLH
2 Nurses, 1 health care assistant, 1 recovery nurse per session	68,750	275	Source: UCLH
Sterilisation	13,750	55	Source: UCLH
Pathology	36,250	145	Source: UCLH
Administration	10,000	40	Source: UCLH
Overheads (endoscopy suite, portering, facilities, drug costs) and Indirect costs	86,000	344	Source: UCLH
Total cost of EBUS-TBNA	345,500	1382	

Supplementary Table E2: Clinical characteristics of patients with isolated mediastinal lymphadenopathy undergoing mediastinoscopy between 2007 and 2008

	Mediastinoscopy only (n=68)
Age	
< 30	3 (4%)
30 – 49	25 (37%)
50 – 69	29 (43%)
>69	11 (16%)
Median (range)	53 (25 – 85)
Gender	
Male	38 (56%)
Female	30 (44%)
Ethnicity	
Caucasian	36 (53%)
Asian	22 (32%)
African	9 (13%)
Caribbean	0 (0%)
Other	1 (1%)
Symptoms	
Cough	31 (46%)
Dyspnoea	8 (12%)
Weight loss	8 (12%)
Fevers / night sweats	5 (7%)
Chest pain	10 (15%)
Other	2 (3%)
None	4 (6%)
Final Diagnosis	
Sarcoidosis Stage 1	31 (46%)
Sarcoidosis Stage 2	2 (3%)
Tuberculosis	17 (25%)
Lymphoma	5 (7%)
Extra-thoracic malignancy	2 (3%)
Lung cancer	1 (1%)
Reactive lymphadenopathy	10 (15%)